CD19 and neoplasm: Unintentional transduction of B-ALL blasts with the CAR transgene during the manufacturing process of CAR-Ts is a rare incidence that leads to the aberrant expression of the CD19-redirected CARs by leukemic cells rendering them resistant to CAR-T-mediated tumor cell eradication (Figure 3) (167).